Primary objective:

- Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice

Secondary objective:

- Treatment satisfaction

Study duration per participant is expected to be approximately 24 weeks

Inclusion Criteria:

• Type 2 diabetes mellitus (T2DM) with oral antidiabetic drug (OAD) ± Glucagon-like-peptide-1 receptor agonist (GLP-1-RA) ± basal insulin (other than insulin glargine 300 U/ml)
• Age ≥75 years incl. patients from outpatient and inpatient care forms
• Glycohaemoglobin (Hba1c) ≥8.0% and ≤11.0%
• Inadequate glycaemic control (HbA1c), defined by the treating physician
• Ability and willingness to perform fasting blood glucose (BG) measurements themselves or with the support of third parties
• Signed consent form

Exclusion Criteria:

• Type 1 diabetes mellitus
• Age <75 years
• Contraindications to insulin glargine 300 U/ml
• Short-acting insulin in medication
• Current participation in clinical research
• Life expectancy <1 year
• Known alcohol or drug abuse
• Mini Mental State Examination Score ≤19

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Type 2 diabetes patients 75 years or older, for whom the treating physician has decided to initiate or switch to a therapy with insulin glargin 300 U/ml as part of the routine clinical practice

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org